Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer

Brachytherapy

Volumn 10, Issue 1, 2011, Pages 9-14

  Pickles, Tom ^a   Morris, W James ^a   Kattan, Michael W ^b   Yu, Changhong ^b   Keyes, Mira ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 78651420329     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2009.12.004     Document Type: Article

References (29)

1. Morris W.J., Keyes M., Palma D., et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology 2009, 73:860-865. discussion 865-867.
2. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008, 179:S20-S24.
3. Feldman-Stewart D., Brennenstuhl S., Brundage M.D., et al. Overall information needs of early-stage prostate cancer patients over a decade: Highly variable and remarkably stable. Support Care Cancer 2009, 17:429-435.
4. Loblaw D.A., Mendelson D.S., Talcott J.A., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004, 22:2927-2941.
5. Chun F.K., Karakiewicz P.I., Briganti A., et al. Prostate cancer nomograms: An update. Eur Urol 2006, 50:914-926. discussion 926.
6. Shariat S.F., Karakiewicz P.I., Suardi N., et al. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: A critical analysis of the literature. Clin Cancer Res 2008, 14:4400-4407.
7. Kattan M.W., Vickers A.J., Yu C., et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009, 115:1005-1010.
8. Klein E.A., Bianco F.J., Serio A.M., et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008, 179:2212-2216. discussion 2216-2217.
9. Chen A.B., D'Amico A.V., Neville B.A., et al. Provider case volume and outcomes following prostate brachytherapy. J Urol 2009, 181:113-118. discussion 118.
10. Cancer UIClCatAJCo, TNM classification of malignant tumors 1992, 1997, 2002, John Wiley & Sons, New York.
11. Morris W.J., Keyes M., Palma D., et al. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:1432-1438.
12. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
13. Heller G., Kattan M.W., Scher H.I. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data. Med Decis Making 2007, 27:380-386.
14. Prostogram Available at:, Last accessed May 2010. http://www.mskcc.org/applications/nomograms/prostate/PreTreatment.aspx.
15. Denham J.W., Steigler A., Wilcox C., et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: Evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 2008, 9:1058-1068.
16. Nielsen M.E., Makarov D.V., Humphreys E., et al. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion-" nadir + 2" Urology 2008, 72:389-393. discussion 394-395.
17. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. J Clin Oncol 2006, 24:3973-3978.
18. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007, 177:540-545.
19. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 65:1487-1493.
20. Kestin L.L., Vicini F.A., Martinez A.A. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 2002, 53:304-315.
21. Zietman A.L., Chung C.S., Coen J.J., et al. 10-Year outcome for men with localized prostate cancer treated with external radiation therapy: Results of a cohort study. J Urol 2004, 171:210-214.
22. Ray M.E., Thames H.D., Levy L.B., et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006, 64:1140-1150.
23. Caloglu M, Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy: Review of a confusing phenomenon. Urology 2009;74:1183-1190.
24. Stock R.G., Stone N.N., Cesaretti J.A. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: Descriptions and implications. Int J Radiat Oncol Biol Phys 2003, 56:448-453.
25. Thompson A, Keyes M, Pickles T, et al. Evaluating the differences in prostate-specific antigen (PSA) kinetics in PSA failure versus PSA bounce after permanent I125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. In press.
26. Vickers A.J., Bianco F.J., Serio A.M., et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 2007, 99:1171-1177.
27. Jeldres C., Suardi N., Walz J., et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008, 54:1306-1313.
28. Stokes E, Tyldesley S, Pickles T. Oncologist case load volume and disease outcomes after curative external beam radiotherapy for localized prostate cancer. In Joint ECCO 15-34TH ESMO Multidisciplinary Congress. Berlin, Germany: European Journal of Cancer Supplements; 2009.
29. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.